https://www.selleckchem.com/products/c-75.html
nd NVP-AUY922 inhibited three HPV-negative HNSCC xenografts in vivo. In conclusion, AREG, STAG3, C19orf57 and CAV1 are key prognostic factors and potential therapeutic targets in HPV-negative HNSCC. NVP-AUY922, fostamatinib and PP-2 may be effective drugs for HPV-negative HNSCC. In conclusion, AREG, STAG3, C19orf57 and CAV1 are key prognostic factors and potential therapeutic targets in HPV-negative HNSCC. NVP-AUY922, fostamatinib and PP-2 may be effective drugs for HPV-negative HNSCC. In this study, we sought to assess healthcare professi
Like
Comment
Share
